Skip to main content
OpenTrials
Completed

NCT Number: NCT01663896

Observational Study of OCT in a Patients Undergoing FFR

The purpose of this study is to define and evaluate optical coherence tomography (OCT) stent guidance parameters through prospective data collection in percutaneous coronary intervention (PCI) procedures of de novo lesions.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Optical coherence tomography (OCT) is an imaging modality that uses near-infrared light to produce high resolution, real-time images that are clearer and more quickly produced than those produced by intravascular ultrasound (IVUS). OCT imaging is performed utilizing an imaging catheter with a single optical fiber core that both emits light and records its reflection while simultaneously rotating 360° during continuous pullback within the coronary artery. Fractional Flow Reserve (FFR) is a pressure-derived, lesion-specific, physiological index determining the hemodynamic severity of intracoronary lesions. FFR is measured by placing a pressure guidewire across the lesion of interest and pharmacologically inducing hyperemia. The ratio of distal to proximal pressure allows the physician to physiologically determine if the narrowing is the cause of ischemia. the goal of this study is to define new parameters for stent optimization, benefitting from the unique Fourier-domain (FD-OCT) capabilities.

This stage I study will identify the parameters which will be prospectively tested in a second stage II protocol.

In hospital, 30 day, and 12 month outcomes data will be correlated with OCT baseline findings in order to identify optimal stent implant parameters.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Patient provides signed written informed consent before any study-specific procedure.
  • De novo coronary artery disease in target vessel.
  • Single or multi vessel disease. For multi vessel disease up to two vessels and three lesions treated, with no more than two lesions per vessel. Vessel is defined as, left anterior descending, left circumflex, and right coronary arteries. Any branch within the vessel is considered part of the vessel.
  • Elective or ad hoc PCI, stable angina, acute coronary syndrome (unstable angina and NSTEMI).
  • Angiographically significant (>50% visual estimation) stenosis present in at least one native coronary artery.
  • Mandatory use of FFR and OCT pre and post PCI. PCI strongly recommended in subjects with an FFR ≤ 0.80 in target vessel.

Exclusion criteria

  • Subjects with STEMI, emergent PCI, or in cardiogenic shock.
  • Subjects with target left main lesion.
  • Subjects with restenosis or stent thrombosis in the target vessel.
  • Planned use of bare metal stent.
  • Known renal insufficiency (examples being but not limited to eGFR < 60 ml/kg/m2, serum creatinine ≥ 2.5 mg/dL, or on dialysis).
  • Aorto-ostial lesion location within 3 mm of the aorta junction (both right and left).
  • Extreme angulation (> 90°) or excessive tortuosity (> two 45° angles) proximal to or within the target lesion.
  • Vessel(s) and lesion(s) not amenable for PCI, for example diffuse disease.
  • Any other medical condition that in the opinion of the investigator will interfere with patient safety or study results.
  • Currently participating in another clinical study that interferes with study results.
  • Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure.
  • Life expectancy less than 1 year.
  • Potential for non-compliance to protocol requirements and follow-up.
  • Planned or prior heart transplantation or listed for heart transplant.
  • Any condition that precludes the subject from undergoing PCI, for example subjects with heparin induced thrombocytopenia, or contrast allergy.

Treatment and study plan

OCT stent guidance

Device

Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT

Primary outcomes

  1. Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting

    Time frame: In-hospital until discharge

    Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes in-hospital.

  2. Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting

    Time frame: 30 Days

    Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes through 30 days

  3. Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting (Academic Research Consortium(ARC))

    Time frame: 12 months

    Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes through 12 months

Secondary outcomes

  1. Percentage of Change in Physician Decision-making Pre and Post PCI Due to OCT

    Time frame: 1 Year

    Assessment of OCT on Physician Decision Making includes:

    • Frequency of changes in treatment strategy based on OCT parameter real time assessment vs. angiographic assessment
    • OCT parameters as assessed by Core Lab

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention Stage I (ILUMIEN I)

Acronym: ILUMIEN I

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Aug 13, 2012
Registry last updated
Jul 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.